Evidence map›Paper›PMID 42557961›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Sex specificity of resistance to caTAUstrophe.

Maria Carrigan, Colin Birkenbihl, Hannah M Klinger, Oliver Langford, Gillian T Coughlan, Mabel Seto, Jane A Brown, Annie Li, Madison Cuppels, Michael Properzi and 12 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Maria CarriganAlzheimer Center Neurology, Vrije Universiteit, Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0001-3506-9708
Colin BirkenbihlMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Hannah M KlingerMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Oliver LangfordAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Gillian T CoughlanMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mabel SetoBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jane A BrownMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Annie LiMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Madison CuppelsMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Michael ProperziMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jasmeer ChhatwalMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Julie PriceMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Aaron SchultzMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Dorene RentzBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Rebecca AmariglioMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Harm J KrugersFaculty of Science, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
Rik OssenkoppeleAlzheimer Center Neurology, Vrije Universiteit, Amsterdam, The Netherlands.
Keith JohnsonMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Reisa SperlingBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Michael DonohueAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Rachel F BuckleyMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Funding

ADRC Consortium for Clarity in ADRD Research Through ImagingU01AG082350 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sarah Biber, BRADFORD C DICKERSON · 2023 to 2026
$90.0M
MVP Data Integration into the ADSP Phenotype Harmonization ConsortiumU24AG074855 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUCCARO, MICHAEL L, HOHMAN, TIMOTHY J · 2021 to 2025
$37.5M
Sex-Specific Genetic Drivers of Alzheimer's Disease EndophenotypesR01AG073439 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Logan C Dumitrescu · 2021 to 2026
$4.8M
Building predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0M
The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5M
Menopause, hormone therapy and Alzheimer's disease clinicopathology: An in vivo perspectiveK99AG083063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI COUGHLAN, GILLIAN THERESA · 2024 to 2025
$269k
Alzheimer Nederland WE.03-2021-03Alzheimer Nederland WE.08-2024-06European Research Council 949570NIA NIH HHS DP2 AG082342NIA NIH HHS DP2AG082342NIA NIH HHS K99 AG083063NIA NIH HHS R01 AG073439NIA NIH HHS R01AG073439NIA NIH HHS R01 AG079142NIA NIH HHS R01AG079142NIA NIH HHS U01 AG082350NIA NIH HHS U01AG082350NIA NIH HHS U24 AG074855NIA NIH HHS U24AG074855
6 · The paper itself

Abstract

introductionAs amyloid beta (Aβ) accumulates, tau pathology spreads beyond medial temporal lobe (MTL) into neocortical (NEO) regions, though some older adults resist this progression, or what we call here "caTAUstrophe." Given previous evidence of higher tau levels in women, we tested how tau resistance presented in men and women separately.

methodsEmploying data from 872 Aβ+ older adults across three cohorts, we trained sex-specific penalized linear regression models in individuals experiencing caTAUstrophe (females: N

resultsRelative feature importance in sex-specific expectation models differed in 97.7% of variables (false discovery rate-adjusted p value < 0.001). Age and Aβ burden associated with male resistance, while Clinical Dementia Rating, latent Preclinical Alzheimer's Cognitive Composite, and adjusted hippocampal volume were associates in both sexes. DISCUSSION: Our study highlights sex-specific biological and clinical factors in the prediction of NEO tau and associates of resistance. Understanding sex-specific resistance pathways informs targeted Alzheimer's interventions.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesSex Characteristicstau ProteinsAgedAged, 80 and overFemaleHumansMagnetic Resonance ImagingMaleAmyloid beta-Peptidestau ProteinsAlzheimer's diseaseglobal cognitioninverse learning approachmagnetic resonance imaging (MRI)neocortical tau resistance

Identifiers

PMID42557961
PMCPMC13444718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.